Cronos Group Annual Meeting Voting Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: Newsfilter
- Shareholder Participation: At the Annual Meeting held on June 18, 2026, shareholders voted on 271,828,759 common shares, representing 72.24% of the total outstanding shares, indicating strong shareholder engagement and governance oversight.
- Director Election Results: All nominated directors received over 93.6% of the votes in favor, with Jason Adler and Darren Broughton both achieving 99.42% support, reflecting strong confidence in the current board's leadership.
- Executive Compensation Resolution: An advisory resolution on executive compensation was approved with 99.09% of votes in favor, and shareholders decided to hold annual advisory votes on executive pay, demonstrating ongoing shareholder interest in compensation practices.
- Auditor Appointment: Shareholders approved Davidson & Company LLP as the independent auditor for fiscal year 2026 and authorized the board to determine the auditor's remuneration, ensuring financial transparency and compliance within the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.860
Low
2.30
Averages
2.72
High
3.14
Current: 2.860
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company's diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cronos Group Appoints New Broker for Share Repurchases
- Broker Change: Cronos Group has appointed ATB Capital Markets Corp. as its new broker for share repurchases, replacing Virtu Canada Corp., aiming to optimize its repurchase operations on the TSX and other alternative trading systems.
- Continuation of Repurchase Program: This broker change occurs within the framework of Cronos's previously announced share repurchase program, demonstrating the company's ongoing commitment to enhancing shareholder value while reflecting its adaptability in market fluctuations.
- Brand Portfolio Development: Cronos is focused on scaling its leading consumer goods product lines through research and innovation, with brands including Spinach®, PEACE NATURALS®, LIT™, and Lord Jones®, indicating a diversified strategy in the global cannabis market.
- Forward-Looking Information Disclosure: The company notes that all non-historical information may constitute forward-looking statements, emphasizing management's cautious approach in the face of business, economic, and competitive risks, and reminding investors to maintain reasonable expectations regarding future performance.
See More
Cronos Group Annual Meeting Voting Results
- Shareholder Participation: At the Annual Meeting held on June 18, 2026, shareholders voted on 271,828,759 common shares, representing 72.24% of the total outstanding shares, indicating strong shareholder engagement and governance oversight.
- Director Election Results: All nominated directors received over 93.6% of the votes in favor, with Jason Adler and Darren Broughton both achieving 99.42% support, reflecting strong confidence in the current board's leadership.
- Executive Compensation Resolution: An advisory resolution on executive compensation was approved with 99.09% of votes in favor, and shareholders decided to hold annual advisory votes on executive pay, demonstrating ongoing shareholder interest in compensation practices.
- Auditor Appointment: Shareholders approved Davidson & Company LLP as the independent auditor for fiscal year 2026 and authorized the board to determine the auditor's remuneration, ensuring financial transparency and compliance within the company.
See More
Cronos Group Initiates Share Repurchase Program
- Repurchase Program Launch: Cronos Group has filed a notice of intention for a normal course issuer bid with the Toronto Stock Exchange, which has been accepted, indicating the company's confidence in its stock value as the program commenced on May 14, 2026, and is expected to end on May 13, 2027.
- Repurchase Scale: The company intends to repurchase up to $50 million of common shares, representing approximately 5.02% of its 373 million issued shares, which is expected to enhance earnings per share and improve shareholder returns.
- Trading Flexibility: Cronos can execute repurchases through various trading systems, including NASDAQ and other U.S. markets, with a daily limit of 53,968 shares on the TSX, demonstrating its operational flexibility in capital management.
- Regulatory Exemption: The company received an exemption from the Ontario Securities Commission, allowing it to repurchase shares on U.S. markets beyond the limits set by Canadian law, further strengthening its capital management strategy.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Cronos' Spinach® Becomes Top-Selling Vape Brand in Canada
- Market Share Leadership: Cronos Group's Spinach® vape captured 10.4% of the Canadian vape market in April 2026, maintaining this leading position since January 2026, demonstrating strong consumer appeal and loyalty.
- Innovation-Driven Products: Spinach® vapes utilize high-purity extracts and advanced hardware to deliver high-quality, flavorful, and consistent experiences for adult consumers, further solidifying its competitive edge in the rapidly growing vape market.
- New Product Launches: The brand plans to introduce several new SKUs this summer, including three new flavors for the Spinach PUFFERZ™ all-in-one vape and its first limited-time offer Orange Vanilla Twist vape, which is expected to drive sales growth and attract new customers.
- Global Expansion Strategy: CEO Mike Gorenstein emphasized that Spinach®'s success in Canada validates the effectiveness of its product innovation engine and builds confidence for future expansion of cannabinoid products globally.
See More
Cronos Group Appoints New Broker for Share Repurchases
- Broker Change: Cronos Group has appointed ATB Capital Markets Corp. as its new broker for share repurchases, replacing Virtu Canada Corp., aiming to optimize its repurchase operations on the TSX and other alternative trading systems.
- Continuation of Repurchase Program: This broker change occurs within the framework of Cronos's previously announced share repurchase program, demonstrating the company's ongoing commitment to enhancing shareholder value while reflecting its adaptability in market fluctuations.
- Brand Portfolio Development: Cronos is focused on scaling its leading consumer goods product lines through research and innovation, with brands including Spinach®, PEACE NATURALS®, LIT™, and Lord Jones®, indicating a diversified strategy in the global cannabis market.
- Forward-Looking Information Disclosure: The company notes that all non-historical information may constitute forward-looking statements, emphasizing management's cautious approach in the face of business, economic, and competitive risks, and reminding investors to maintain reasonable expectations regarding future performance.
See More
Cronos Group Annual Meeting Voting Results
- Shareholder Participation: At the Annual Meeting held on June 18, 2026, shareholders voted on 271,828,759 common shares, representing 72.24% of the total outstanding shares, indicating strong shareholder engagement and governance oversight.
- Director Election Results: All nominated directors received over 93.6% of the votes in favor, with Jason Adler and Darren Broughton both achieving 99.42% support, reflecting strong confidence in the current board's leadership.
- Executive Compensation Resolution: An advisory resolution on executive compensation was approved with 99.09% of votes in favor, and shareholders decided to hold annual advisory votes on executive pay, demonstrating ongoing shareholder interest in compensation practices.
- Auditor Appointment: Shareholders approved Davidson & Company LLP as the independent auditor for fiscal year 2026 and authorized the board to determine the auditor's remuneration, ensuring financial transparency and compliance within the company.
See More
Cronos Group Initiates Share Repurchase Program
- Repurchase Program Launch: Cronos Group has filed a notice of intention for a normal course issuer bid with the Toronto Stock Exchange, which has been accepted, indicating the company's confidence in its stock value as the program commenced on May 14, 2026, and is expected to end on May 13, 2027.
- Repurchase Scale: The company intends to repurchase up to $50 million of common shares, representing approximately 5.02% of its 373 million issued shares, which is expected to enhance earnings per share and improve shareholder returns.
- Trading Flexibility: Cronos can execute repurchases through various trading systems, including NASDAQ and other U.S. markets, with a daily limit of 53,968 shares on the TSX, demonstrating its operational flexibility in capital management.
- Regulatory Exemption: The company received an exemption from the Ontario Securities Commission, allowing it to repurchase shares on U.S. markets beyond the limits set by Canadian law, further strengthening its capital management strategy.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Cronos' Spinach® Becomes Top-Selling Vape Brand in Canada
- Market Share Leadership: Cronos Group's Spinach® vape captured 10.4% of the Canadian vape market in April 2026, maintaining this leading position since January 2026, demonstrating strong consumer appeal and loyalty.
- Innovation-Driven Products: Spinach® vapes utilize high-purity extracts and advanced hardware to deliver high-quality, flavorful, and consistent experiences for adult consumers, further solidifying its competitive edge in the rapidly growing vape market.
- New Product Launches: The brand plans to introduce several new SKUs this summer, including three new flavors for the Spinach PUFFERZ™ all-in-one vape and its first limited-time offer Orange Vanilla Twist vape, which is expected to drive sales growth and attract new customers.
- Global Expansion Strategy: CEO Mike Gorenstein emphasized that Spinach®'s success in Canada validates the effectiveness of its product innovation engine and builds confidence for future expansion of cannabinoid products globally.
See More
